Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273871|
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : March 8, 2011
|Condition or disease||Intervention/treatment||Phase|
|Graft Rejection Kidney Failure Kidney Transplantation||Drug: Cyclosporin or tacrolimus||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||190 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.|
|Study Start Date :||January 2002|
|Actual Study Completion Date :||September 2006|
- Difference between treatment groups in renal function at 12 months.
- Incidence of acute rejection, patient and graft survival at 12 months, labs and physical examinations, quality of life etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273871
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|
|Principal Investigator:||Trial Manager||For United Kingdom and Ireland, email@example.com|